OSR HOLDINGS INC.

At the annual meeting, shareholders voted to reelect seven directors and approved the independent auditor, executive compensation, and an increase in the authorized common shares; approximately 60.05% of outstanding shares were represented. Each re-elected director received at least 15.1 million votes in favor. OSR Health also entered into a definitive agreement to acquire the intellectual property of VAXIMM (VXM01) for $30 million; the patents run through 2038. The company is officially changing its name and will forgo a reverse stock split for now in order to restore NASDAQ compliance operationally instead. » More on de.investing.com

OSR Health has, effective June 11, changed the company name from OSR Holdings to OSR Health and reactivated its corporate status in Delaware. Common stock and warrants will continue to trade under the symbols OSRH and OSRHW; shareholders do not need to take any action. At the same time, the company announced the acquisition of the VXM01 IP portfolio from VAXIMM for $30 million and a licensing agreement with BCM Europe with milestone payments of up to $815 million, appointed Yeiseok Kim as COO, waived a reverse stock split, and closed a capital-structure transaction with the White Lion GBM Innovation Fund. » More on de.investing.com

OSR Holdings has appointed Yeiseok Kim as chief operating officer effective March 26, 2026. Kim was previously a senior analyst at subsidiary OSR Holdings Co., Ltd. and will receive a base salary of 240,000,000 KRW and the opportunity to participate in an equity-based compensation program. The company also completed a capital-structure transaction with the White Lion GBM Innovation Fund, revised a global license agreement with BCM Europe for VXM01, and is exploring partnerships in China as well as potential licensing talks with SillaJen. » More on de.investing.com